Introduction {#Sec1}
============

Extracorporeal membrane oxygenation (ECMO) provides cardiorespiratory support to patients who have failed initial, conventional treatment \[[@CR1], [@CR2]\]. In pediatric populations, ECMO is used for organ support in cases of respiratory failure, cardiac failure, and as an adjunct to cardiopulmonary resuscitation (E-CPR) during cardiac arrest \[[@CR3]--[@CR6]\]. ECMO can also serve as a bridge to selected medical or surgical therapies, including ventricular assist device (VAD), and heart or lung transplant \[[@CR7], [@CR8]\].

With the use of ECMO evolving \[[@CR9]\], there is a growing need to understand its impact on long-term patient outcomes and system cost. The majority of evidence surrounding the efficacy of ECMO in the pediatric population comes from institutional cohort studies, as very few randomized trials have been performed \[[@CR2]\]. Across the world, ECMO utilization was historically more common among neonates than older children; however, this trend has changed over the last decade with an increase in pediatric cardiac and pediatric respiratory utilization \[[@CR9]\]. For patients with respiratory failure, in-hospital mortality among those receiving ECMO (largely venovenous \[VV-ECMO\]) was approximately 25% and did not differ from propensity-matched controls \[[@CR10]\]. However, in the pediatric population, venoarterial ECMO (VA-ECMO) is more common. Hospital mortality in this population has been reported between 45 and 55% \[[@CR9]\].

ECMO has been used for critically ill children in Canada since 1989, but little has been published regarding longer-term outcomes or associated costs, and this has been identified as an important avenue for future research in extracorporeal life support \[[@CR11], [@CR12]\]. Most importantly, there are key gaps in knowledge related to costs incurred in the long-term. We conducted a population-based cohort analysis to evaluate the short- and long-term outcomes and costs of critically ill children receiving ECMO for cardiorespiratory support. We hypothesized that while many ECMO patients may die in hospital, the large majority who survived to discharge would still be alive at 5 years and that patient costs would largely reflect inpatient costs during the index hospitalization.

Methods {#Sec2}
=======

Data sources and setting {#Sec3}
------------------------

This was a population-based, retrospective cohort study, conducted using health administrative databases in Ontario, Canada. Ontario has a population of approximately 13 million inhabitants, and necessary medical services are publicly funded through a single-payer healthcare system. These databases record all medically necessary healthcare services, as well as physician, hospital, and demographic information for provincial residents. These data are held and linked at ICES, an independent, non-profit custodian of health data. ICES is funded by an annual grant from the Ontario Ministry of Health and Long-term Care. In Ontario, pediatric ECMO is provided at only two centers: The Hospital for Sick Children (Toronto, ON) and the Children's Hospital of Eastern Ontario (Ottawa, ON). These institutions are regional, academic, university-affiliated children's hospitals with cardiothoracic surgery programs. ECMO care in children is offered across Canada in similarly structured provincial pediatric ECMO centers. Cannulation procedures are conducted by surgeons (pediatric cardiothoracic or general surgeons), and medical/cardiac intensive care is centralized in "closed" units with pediatric intensive care physicians with training in ECMO. Bedside care involves a mix of speciality trained critical care nurses, respiratory therapists, ECMO specialists or perfusionists, and other allied health professionals.

We linked the following databases at the individual level using healthcare identification numbers: (1) The Canadian Institute for Health Information Discharge Abstract Database, (2) The Ontario Health Insurance Plan (OHIP) Claims Database, (3) The Registered Persons Database, (4) The Home Care Database, (5) The National Ambulatory Care Reporting System, (6) The National Rehabilitation Reporting System, (7) The Continuing Care Reporting System, and (8) Statistics Canada Census data.

This study was approved by The Ottawa Health Science Network Research Ethics Board.

Patients {#Sec4}
--------

We included all pediatric patients (\< 18 years of age) receiving ECMO in Ontario between October 1, 2009, and March 31, 2017. Patients were identified using the presence of an inpatient ECMO intervention code, obtained by searching through inpatient data captured by the Discharge Abstract Database (all codes displayed in Supplemental Table [1](#MOESM1){ref-type="media"}), as performed previously in adult patients \[[@CR13]\].

We identified pediatric complex chronic conditions (CCC) from our administrative data using the methodology described by Feudtner et al. \[[@CR14]\]. The CCC is preferentially used to identify comorbidities in children. We used the same codes as previous studies identifying CCC from the ICES administrative databases \[[@CR15]\].

Outcomes following ECMO initiation were expected to be strongly associated with the indication (cardiac versus respiratory failure) \[[@CR16]\], and therefore, we further analyzed patients on this basis. Since data related to ECMO mode (e.g., VV-ECMO vs. VA-ECMO) were unavailable, patients were categorized as either "Respiratory Failure" or "Cardiac Failure," based upon the ICD-10 most responsible diagnosis (see Supplemental Table [1](#MOESM1){ref-type="media"} for categorization). These categories were chosen in order to align with the Extracorporeal Life Support Organization (ELSO) database. Categorization was performed by two pediatric intensivists who also serve as medical directors for ECMO at the two pediatric centers in Ontario that provide this therapy (SD, AMG). Neonatal patients (0--30 days of age) were analyzed separately.

Outcomes {#Sec5}
--------

The primary outcome was survival, which was measured to hospital discharge, as well as at 7 days, 30 days, 1 year, 2 years, and 5 years following initiation of ECMO. Time to ECMO initiation was estimated by calculating the difference between the hospital admission date and the date on which the ECMO intervention code was coded. Length of stay for the hospitalization was reported from the date of hospital admission to the date of discharge, or in-hospital death. Discharge disposition was determined using a hierarchy approach (Supplemental Table [3](#MOESM3){ref-type="media"}). Transplant and VAD implantation (short- or long-term) were determined using the relevant procedural codes in the Discharge Abstract Database.

Among this cohort, we examined the total and sector-specific direct healthcare costs accumulated in the year following the date of the index hospital admission (including the admission itself). We obtained all records of healthcare use paid for by the Ontario Ministry of Health and Long-term Care following admission. We estimated the costs associated with each record using previously described methods developed for health administrative data \[[@CR17]\]. We used a top-down approach through case-mix methodology for sectors that use global budgets (e.g., hospital, complex continuing care, rehabilitation). Sectors for which each use has an associated fee payment (e.g., drug costs, physician remuneration) have costs estimated directly. All costs were expressed in 2018 Canadian dollars, and past costs were inflated using the healthcare-specific yearly Consumer Price Index reported by Statistics Canada.

Cell sizes with ≤ 5 patients are suppressed, as per ICES regulations, to protect patient confidentiality, though data were still analyzed.

Statistical analyses {#Sec6}
--------------------

All statistical analyses were conducted using SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC). We present data as mean values, with standard deviation (SD), or medians, with interquartile range (IQR), where appropriate. Student's *t* test (parametric values), Mann-Whitney test (non-parametric values), and *χ*^2^ (for categorical values) were performed to determine between-group differences. The Kaplan-Meier survival curves were used to measure trends of 1-year survival.

Results {#Sec7}
=======

We included a total of 342 patients in the analysis. Of these, 103 (30.1%) were neonatal (0--30 days old), 169 (49.4%) were categorized as "Cardiac Failure," and 70 (20.5%) were categorized as "Respiratory Failure." Patient characteristics of the study cohort are shown in Table [1](#Tab1){ref-type="table"}. Mean age was 2.9 years (SD 5.0 years), and 54.7% were male. Of the total patient cohort, 25.4% came from the lowest income quintile, compared with 14.3% from the highest income quintile. Median time to ECMO initiation from the date of hospital admission was 5 days (IQR 1--13 days). At least one CCC was present in 274 patients (79.9%), with the most common CCC being cardiovascular, which was present in 217 patients (63.3%). Table 1Characteristics of pediatric patients requiring extracorporeal membrane oxygenation in Ontario, Canada (2009--2016)VariableOverall (*n* = 342)Neonatal (*n* = 103)Cardiac failure (*n* = 169)Respiratory failure (*n* = 70)Sex, *n* (%) Male187 (54.7)66 (64.1)79 (46.7)42 (60.0) Female155 (45.3)37 (35.9)90 (53.3)28 (40.0)Age, years (non-neonatal) or days (neonatal), mean (SD)2.9 (5.0)9.6 (7.6)3.0 (4.7)7.0 (6.2)Income, *n* (%) Lowest87 (25.4)33 (32.0)37 (21.9)17 (24.3) Low64 (18.7)21 (20.436 (21.3)7 (10.0) Middle72 (21.1)22 (21.4)35 (20.7)15 (21.4) High67 (19.6)15 (14.6)33 (19.5)19 (27.1) Highest49 (14.3)12 (11.7)25 (14.8)12 (17.1) Unknown\*\*\*\*Rurality, *n* (%) Urban305 (89.2)93 (90.3)148 (87.6)64 (91.4) Rural35 (10.2)10 (9.7)19 (11.2)6 (8.6)Time to ECMO from admission, days, median (IQR)5 (1--13)5 (2--11)5 (1--14)6 (1--19)Chronic complex conditions, *n* (%)^a^ Any complex chronic condition274 (79.9)81 (78.6)140 (82.8)53 (74.6) Prematurity52 (15.2)18 (17.5)23 (13.6)11 (15.5) Cardiovascular217 (63.3)61 (59.2)132 (78.1)24 (33.8) Metabolic19 (5.5)0 (0.0)7 (4.1)12 (16.9) Other congenital or genetic abnormality58 (16.9)17 (16.5)31 (18.3)10 (14.1)^a^Adapted from Feudtner et al. \[[@CR14]\]. *Abbreviations*: *SD* standard deviation, *ECMO* extracorporeal membrane oxygenation, *IQR* interquartile rangeRange provided due to small cell sizes\*Denotes ≤ 5 patients

Table [2](#Tab2){ref-type="table"} shows patient outcomes for the entire cohort and by individual subgroups. A total of 193 patients (56.4%) survived to hospital discharge. The 1-year, 2-year, and 5-year survival for the cohort were 51.5%, 50.0%, and 42.1%, respectively. Survival to discharge was lower among respiratory failure patients (51.4%), as compared to cardiac failure patients (60.4%). Among neonatal patients, 53.4% survived to hospital discharge. Survival at 1 year, 2 years, and 5 years were 47.6%, 45.6%, and 42.9%, respectively. Median overall hospital length of stay was 26 days (IQR 11--61 days). Fifty-nine patients (17.3%) were transitioned from ECMO to VAD. ECMO was followed by heart transplant in 13 patients (3.8%) and lung transplant in 11 patients (3.2%). Among patients surviving to discharge, 192 (99.5%) were discharged home, though 97 of these patients (50.5%) required homecare. In the year following hospitalization, 57.5% of survivors had at least one Emergency Department visit, and 43.0% of survivors required hospital re-admission. Patient outcomes stratified by age are shown in Fig. [1](#Fig1){ref-type="fig"}. Table 2Short- and long-term outcomes of pediatric patients requiring extracorporeal membrane oxygenation in Ontario, Canada (2009--2017)VariableOverall (*n* = 342)Neonatal (*n* = 103)Cardiac failure (*n* = 169)Respiratory failure (*n* = 70)*P* valueSurvival following ECMO initiation, *n* (%) To hospital discharge193 (56.4)55 (53.4)102 (60.4)36 (51.4)0.34 7 days253 (74.0)81 (78.6)127 (75.1)45 (64.3)0.10 30 days217 (63.5)62 (60.2)115 (68.0)40 (57.1)0.20 1 years176 (51.5)49 (47.6)93 (55.0)34 (48.6)0.42 2 years171 (50.0)47 (45.6)91 (53.8)33 (47.1)0.37 5 years^a^75 (42.1)24 (42.9)38 (45.2)13 (34.2)0.51Hospital length of stay, days, median (IQR)26 (11--61)24 (14--53)29 (11--72)21 (8--55)0.21Ventricular assist device during hospitalization, *n* (%)59 (17.3)17 (16.5)29 (17.2)13 (18.6)0.94Transplant during hospitalization, *n* (%) Heart transplant13 (3.8)\*13 (7.7)\*\< 0.001 Lung transplant11 (3.2)\*\*10 (14.3)\< 0.001Discharge disposition among survivors, *n* (%)^b^0.78 Home (without homecare)95 (49.2)26 (47.2)51 (50.0)18 (50.0) Home (with homecare)97 (50.3)29 (52.7)50 (49.0)18 (50.0)Emergency department visit following discharge, *n* (%)^b^ Within 30 days48 (24.9)14 (25.5)23 (22.5)11 (30.6)0.90 Within 90 days78 (40.4)22 (40.0)42 (41.1)14 (38.9)0.66 Within 1 year111 (57.5)27 (49.1)58 (56.9)26 (72.2)0.25Hospital readmissions following discharge, *n* (%)^b^ Within 30 days35 (18.1)12 (21.8)15 (14.7)8 (22.2)0.71 Within 90 days62 (32.1)15 (27.3)33 (32.4)14 (38.9)0.53 Within 1 year83 (43.0)18 (32.7)43 (42.2)22 (61.1)0.10*Abbreviations*: *ECMO* extracorporeal membrane oxygenation, *IQR* interquartile range^a^Five-year mortality values only include patients between 2009 and 2014 (*n* = 178 for "Overall," *n* = 56 for "Neonatal," *n* = 84 for "Cardiac failure," *n* = 38 for "Respiratory failure")^b^Only includes patients who survived to hospital discharge (*n* = 193 for "Overall," *n* = 55 for "Neonatal," *n* = 102 for "Cardiac failure," *n* = 36 for "Respiratory failure")\*Denotes ≤ 5 patientsFig. 1Outcomes of critically ill pediatric patients requiring extracorporeal membrane oxygenation in Ontario (*n* = 342), stratified by age bracket. **a** Mortality. **b** Disposition among patients surviving to hospital discharge. **c** Hospital readmission in the first year among patients surviving to hospital discharge

The Kaplan-Meier curves depicting survival in the first year following ECMO initiation for the entire cohort and by ECMO indication are shown in Fig. [2](#Fig2){ref-type="fig"}. The greatest proportion of deaths occurred in the first 30--40 days following ECMO initiation. We compared patients who died in-hospital with those that survived to discharge (Supplemental Tables [5](#MOESM5){ref-type="media"}, [6](#MOESM6){ref-type="media"}, [7](#MOESM7){ref-type="media"}). A shorter median time to ECMO initiation was associated with survival among the "Neonatal" and "Cardiac Failure" groups. Fig. 2The Kaplan-Meier curves depicting survival in the first year following extracorporeal membrane oxygenation among critically ill pediatric patients in Ontario, Canada (2009--2017) (*n* = 342)

Importantly, we evaluated median health system costs among pediatric patients receiving ECMO in the 1-year following hospital admission (including the admission itself) (Table [3](#Tab3){ref-type="table"}). Median total costs among all patients were \$147,957 (IQR \$70,571--\$300,295). The predominant contributor to overall costs was inpatient costs of the index hospitalization (median \$119,197, IQR \$57,839--\$250,675). Mean costs are shown in Supplemental Table [8](#MOESM8){ref-type="media"}. Table 3Median (interquartile range) 1-year costs following admission of pediatric patients requiring extracorporeal membrane oxygenation in Ontario, Canada (2009--2017)Cost sectorOverall (*n* = 342)Neonatal (*n* = 103)Cardiac failure (*n* = 169)Respiratory failure (*n* = 70)*P* valueAcute care sectors Inpatient119,197 (57,839--250,675)117,885 (66,597--217,202)135,879 (61,181--289,533)96,762 (41,416--194,397)0.15 Emergency department143 (0--807)0 (0--698)111 (0--806)475 (0--965)0.04Continuing care sectors Complex continuing care0 (0--0)0 (0--0)0 (0--0)0 (0--0)0.60 Long-term care0 (0--0)0 (0--0)0 (0--0)0 (0--0)1.00 Rehabilitation0 (0--0)0 (0--0)0 (0--0)0 (0--0)1.00 Homecare0 (0--1734)0 (0--1628)0 (0--1636)0 (0--2633)0.92Outpatient care sectors Outpatient clinics758 (319--2307)722 (0--2287)780 (332--1946)737 (0--3510)0.84 Laboratory (OHIP)0 (0--0)0 (0--0)0 (0--0)0 (0--0)0.07 Drugs (Ontario Drug Benefit Program)0 (0--548)0 (0--224)0 (0--804)0 (0--1183)0.66Physician billings18,970 (10,059--31,348)17,649 (12,106--24,460)21,529 (11,492--34,973)17,902 (7209--28,076)0.19Total costs147,957 (70,571--300,295)141,423 (84,755--256,128)173,303 (81,888--328,018)147,957 (70,571--300,295)0.29Total cost/survivor to discharge412,358365,393412,284484,328All values in Canadian dollars. *Abbreviations*: *SD* standard deviation, *OHIP* Ontario Health Insurance Plan

Discussion {#Sec8}
==========

We conducted a population-based cohort study among critically ill children receiving ECMO for cardiorespiratory support to identify long-term outcomes and health system costs in the first year. Survival to hospital discharge in this provincial-wide cohort was 56.4%. This did not decrease substantially after 1 year, but moderate decrease was seen at 2 years and 5 years following ECMO initiation. The number of patients in the cohort from the lowest income quintile was nearly double that of patients from the highest income quintile. Patients predominantly received ECMO for cardiac failure, and survival to hospital discharge was markedly higher in this population, as compared to those with respiratory failure. The large majority of survivors to discharge (99.6%) were ultimately able to be discharged home. Finally, pediatric patients accrued significant hospital-related costs in the year following ECMO initiation, but the majority of these costs were incurred during the inpatient hospitalization, with few costs incurred following discharge. This study provides important information regarding long-term survival and costs following the use of this high-intensity therapy in the care of critically ill pediatric patients.

This cohort represents a contemporary pediatric ECMO sample that spans over 7 years. In-hospital mortality in this overall cohort was similar to that reported in other studies \[[@CR9]\]. Reassuringly, there was relatively little mortality following hospital discharge, and survival rates at 1 year were comparable to hospital discharge rates. Survival at 2 years and 5 years following initiation of ECMO showed a moderate decline. Similar 5-year trends have been previously demonstrated in a population-based pediatric cohort from the UK \[[@CR18]\] and an adult cohort from Ontario \[[@CR13]\]. Therefore, this study supports existing work showing that particularly in patients \> 30 days of age, the long-term survival (up to 5 years) following ECMO is very good among those who survive to hospital discharge. This data has particular value in conversations with patients and caregivers, and can be used to convey prognostication and set expectations for survival in both the short- and long-term, given the existing data. Overall mortality rates were higher among patients with respiratory failure, which is contrary to what has been seen previously \[[@CR8]--[@CR10]\]. Although the reason for this remains unclear, it may reflect the selective use of ECMO at the included centers, as compared to other centers in the ELSO database. For this reason, caution must be exercised in extrapolating the findings from the subgroup analyses to other settings.

Few pediatric patients received heart or lung transplantation following ECMO initiation, which is in large contrast to what is seen in adult patients \[[@CR13]\]. This is in keeping, however, with the practice in pediatrics that has shifted away from using ECMO as a bridge to transplantation, and replaced it by using VAD, given the better outcomes with VAD over ECMO \[[@CR19], [@CR20]\]. Data from the ELSO Registry shows that among patients for whom ECMO was planned as a bridge to heart transplant, only 45% ultimately survived to transplantation, and a third of transplanted patients died before hospital discharge \[[@CR19]\].

Importantly, we investigated long-term costs following utilization of ECMO in critically ill children. While there is emerging literature on the cost-effectiveness of ECMO \[[@CR21], [@CR22]\], and hospital costs for pediatric patients receiving ECMO have been previously published \[[@CR21], [@CR23]--[@CR25]\], our study uniquely describes long-term costs in the year following ECMO initiation. We found that patients supported with ECMO accrued significant costs in the year following their index hospitalization; however, the large majority of these costs reflect the ECMO hospitalization itself, and few costs were incurred following discharge. The median overall costs in our population are similar to what has been previously described among pediatric patients with cardiorespiratory failure \[[@CR26]\]. These costs are also consistent with those seen in other high-resource critically ill populations, such as pediatric patients with traumatic brain injury \[[@CR27]\], or adults with multi-organ failure \[[@CR28]\]. A major focus of current critical care research is the understanding of resource utilization not only in the short-term, but also following discharge \[[@CR29], [@CR30]\]. ECMO particularly falls into this conversation given the significant amount of resources required for its use. Our study shows that while the inpatient costs are significant, the downstream costs are less so, and this has particular importance in healthcare settings where downstream costs are paid for by the patients themselves.

Finally, our work identifies important avenues for future research, especially related to patient outcomes, and selection for ECMO. We compared and contrasted factors associated with survival among children receiving ECMO. We also demonstrated that ECMO was associated with significant inpatient costs. Therefore, to appropriately prognosticate outcome, and optimize patient selection, derivation and validation of a clinical decision instrument is necessary. Ideally, this should be performed using a prospective cohort, and separate instruments for patients with respiratory and cardiac failure should be derived, as has been done in the adult population \[[@CR31], [@CR32]\]. Furthermore, beyond understanding survival, an effort must be made to understand long-term quality of life, as has been done in the adult population \[[@CR33]\]. For patients and caregivers, an appropriate picture of survival following ECMO must also include long-term functional and cognitive outcomes. While this has been performed at the 6-month point following ECMO \[[@CR34], [@CR35]\], longer-term follow-up is required.

In this study, we utilized comprehensive population-level data to investigate the short- and long-term outcomes and costs among critically ill pediatric patients receiving ECMO in Ontario, Canada. This study provides some of the first data related both to long-term outcomes and costs following the critical illness hospitalization in a large representative sample of Canadian pediatric ECMO patients. However, there are limitations to this study. First, ECMO is known to be associated with important complications, including cerebral hemorrhage, stroke, renal failure, and infection \[[@CR36], [@CR37]\]. We did not have validated data related to these complications and therefore are unable to comment on incidence and impact in our cohort. Second, in Ontario, ECMO in pediatric patients is conducted at only two specialized, regional referral centers for cardiac surgery, solid organ transplantation, trauma, and high-risk neonatal care. Since outcomes from ECMO are associated with center-specific frequency of use and volume \[[@CR38]\], these findings are only generalizable to similar organizations with mature ECMO programs in North and South America, Europe, East Asia, Australia, and New Zealand. Third, while we did provide data related to survival and costs incurred following discharge, we did not have data related to quality of life and family burden following discharge. Existing evidence highlights the significant long-term morbidity seen in similar populations \[[@CR39]\]. Finally, while the databases held at ICES are robust and have been used extensively for large population-based studies \[[@CR13], [@CR40]\], there are inherent limitations to the available administrative data. We did not have complete data related to illness severity at the time of hospital admission or ECMO initiation, nor the duration of ECMO. We also did not have data on parameters prior to ECMO initiation, configuration utilized, nor the specific costs attributable to ECMO use from a patient's total inpatient costs. Lastly, we did not have data on mode or cause leading to death during the hospitalization or after discharge, the latter particularly pertinent among patients who initially survived to hospital discharge.

Conclusions {#Sec9}
===========

We found that 55.5% of critically ill pediatric patients requiring ECMO survive to hospital discharge, with relative stabilization of the survival curve at 1, 2, and 5 years following ECMO initiation. Survival was lower among neonates than older children, and among patients with respiratory failure, as compared to cardiac failure. Reassuringly, in this contemporary cohort of children, nearly all patients surviving to hospital discharge were able to be discharged home. While ECMO patients accrued significant inpatient costs, these costs were less than typical high-cost populations, and most importantly, survivors had low healthcare-associated costs in the year following discharge. This work provides novel data regarding the long-term outcomes and costs of critically ill children receiving ECMO for cardiorespiratory support.
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**Additional file 1 : Supplemental Table 1.** Relevant databases and codes utilized for ECMO identification, and International Classification of Diseases, Version 10 (ICD-10) diagnostic codes for categorization. **Additional file 2 : Supplemental Table 2**. Ontario Health Insurance Plan (OHIP), International Classification of Diseases, Version 9 (ICD-9), and Version 10 (ICD-10) diagnostic codes for categorization of comorbidities. **Additional file 3 : Supplemental Table 3.** Hierarchy approach for discharge disposition of those who survived to discharge. **Additional file 4 : Supplemental Table 4.** Most common "Most Responsible Diagnoses" among included patients. **Additional file 5 : Supplemental Table 5.** Comparison of neonatal patients receiving Extra Corporeal Membrane Oxygenation who survive to hospital discharge against those who died in-hospital (*n =* 342). \*≤ 5 patients. ^a^Range provided due to small cell sizes. Abbreviations: SD = standard deviation; ECMO = Extracorporeal Membrane Oxygenation; IQR = interquartile range. **Additional file 6: Supplemental Table 6.** Comparison of patients with cardiac failure receiving Extra Corporeal Membrane Oxygenation who survive to hospital discharge against those who died in-hospital (*n =* 169). \*≤ 5 patients. ^a^Range provided due to small cell sizes. Abbreviations: SD = standard deviation; ECMO = Extracorporeal Membrane Oxygenation; IQR = interquartile range. **Additional file 7 : Supplemental Table 7.** Comparison of patients with respiratory failure receiving Extra Corporeal Membrane Oxygenation who survive to hospital discharge against those who died in-hospital (*n =* 70). \*≤ 5 patients. ^a^Range provided due to small cell sizes. Abbreviations: SD = standard deviation; ECMO = Extracorporeal Membrane Oxygenation; IQR = interquartile range. **Additional file 8 : Supplemental Table 8.** Mean (standard deviation) 1-year costs following admission of pediatric patients requiring Extra Corporeal Membrane Oxygenation in Ontario, Canada (2009-2016). All values in Canadian dollars. Abbreviations: SD = standard deviation; OHIP = Ontario Health Insurance Plan.
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